Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07364513Phase 1Recruiting

Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies

Role: lead

NCT05846646Phase 2Terminated

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Role: lead

NCT04020185Phase 1Completed

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

Role: lead

NCT05846659Phase 2Terminated

Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

Role: lead

NCT06026254Phase 1Active Not Recruiting

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

Role: lead

All 5 trials loaded